Serum levels of cytokeratin-18 (tissue polypeptide-specific antigen) in liver diseases
Version of Record online: 8 NOV 2006
Volume 26, Issue 10, pages 1217–1224, December 2006
How to Cite
Gonzalez-Quintela, A., Mallo, N., Mella, C., Campos, J., Perez, L.-F., Lopez-Rodriguez, R., Tome, S. and Otero, E. (2006), Serum levels of cytokeratin-18 (tissue polypeptide-specific antigen) in liver diseases. Liver International, 26: 1217–1224. doi: 10.1111/j.1478-3231.2006.01380.x
- Issue online: 8 NOV 2006
- Version of Record online: 8 NOV 2006
- Received 3 May 2006,accepted 6 September 2006
- hepatitis virus;
- tissue polypeptide-specific antigen
Abstract: Objective: The tissue polypeptide-specific antigen (TPS, cytokeratin-18, a normal constituent of the hepatocyte cytoskeleton) is a standard tumour marker. This study aimed to evaluate serum TPS levels in patients with liver disease.
Methods: Serum TPS was measured with a commercial immunoassay in 884 individuals (753 outpatients from a liver disease clinic, 131 patients admitted to the hospital with acute liver disease).
Results: Abnormally high (>80 U/l) TPS levels were found in 57.7% (95% CI 54.0–61.3%) of outpatients with liver disease. Elevated TPS levels were observed for all liver diseases, including fatty liver, alcoholic disease, chronic viral hepatitis, autoimmune hepatitis, cholestasis, transplantation, and hepatocarcinoma. TPS levels correlated with liver markers, particularly serum AST. In addition, TPS levels correlated with Knodell's score in patients with chronic hepatitis. TPS was increased in one-third of patients with normal liver enzyme values. Serum TPS levels decreased after specific therapy in patients with hepatitis C and autoimmune hepatitis. Abnormally high TPS levels were found in the vast majority of patients admitted to the hospital, with markedly high (>800 U/l) values being observed in 47.5% (95% CI 36.1–55.7%) of patients with alcoholic liver disease and in 80.8% (95% CI 60.0–92.7%) of patients with acute hepatitis.
Conclusions: Serum TPS (cytokeratin-18) is elevated in patients with non-malignant liver diseases, particularly in those with prominent cytolysis. Further studies are needed to evaluate the use of TPS as a marker of liver disease.